This page is the continuation of reference in support of Section 6b.
REFERENCES
Abd El-Rehim, D.M., Pinder, S.E., Paish, C.E., et al. (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 203, 661–671. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/15141381
Acs, G., Lawton, T.J., Rebbeck, T.R., Livolsi, V.A., Zhang, P.J. (2001). Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 115, 85–98. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/11190811
Albain, K.S., Carey, L., Gradishar, W.J., et al. (2010). Proceedings of the First Global Workshop on Breast Cancer: Pathways to the evaluation and clinical development of novel agents for breast cancer. Clin. Breast Cancer 10, 421–439. (Retrieved November 19th 2014):https://www.ncbi.nlm.nih.gov/pubmed/21147685
Alizadeh, A.A., Ross, D.T., Perou, C.M., van de Rijn, M. (2001). Towards a novel classification of human malignancies based on gene expression patterns. J. Pathol 195, 41–52. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/11568890
Allred, D.C., Bustamante, M.A., Daniel, C.O., Gaskill, H.V., Cruz, A.B. Jr. (1990). Immunocytochemical analysis of estrogen receptors in human breast carcinomas: evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 125, 107–113. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/1688490
Allred, D.C., Harvey, J.M., Berardo, M., Clark, G.M. (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11, 155-168. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/9504686
Carey, L., Winer, E., Viale, G., et al. (2010). Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7, 683–692. (Retrieved November 21st 2014): https://www.ncbi.nlm.nih.gov/pubmed/20877296
De Leeuw, W.J., Berx, G., Vos, C.B., Peterse, J.L., Van de Vijver, M.J., Litvinov, S., Van Roy, F., Cornelisse, C.J., Cleton-Jansen, A.M. (1997). Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183(4), 404. (Retrieved November 14th 2014): https://www.ncbi.nlm.nih.gov/pubmed/9496256
Goldstein, N.S., Hewitt, S.M., Taylor, C.R., et al. (2007). Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol 15, 124–33. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/17525622
Goulding, H., Pinder, S., Cannon, P., et al. (1995). A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 26, 291–4. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/7890280
Harvey, J.M., Clark, G.M., Osborne, C.K., Allred, D.C. (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17, 1474–1481. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/10334533
Lerwill, M.F. (2004). Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 28(8), 1076-91. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/15252316
Nielsen, T.O., Parker, J.S., Leung, S. et al. (2010). A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16, 5222–5232. (Retrieved November 21st 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2970720/
Perou, C.M., Jeffrey, S.S., van de Rijn, M., Rees, C.A. et al. (1999). Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA 96, 9212–9217. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/10430922
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P., Olivier, M. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6), 622-9. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/17311302
Sotiriou C, Pusztai L. (2009). Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790–800. (Retrieved November 19th 2014): https://www.ncbi.nlm.nih.gov/pubmed/19228622
Tse, G.M., Tan, P.H., Lui, P.C., et al. (2007). The role of immunohistochemistry for smooth muscle actin, p63, CD10 and CK14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 2007;60:315–20. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/16698948
Walker, R.A., Hanby, A., Pinder, S.E., Thomas, J., Ellis, I.O. National Coordinating Committee for Breast Pathology Research Subgroup. (2012). Current issues in diagnostic breast pathology. J Clin Pathol 65(9), 771-85. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/22813732
Weslowski, R., Ramaswamy, B. (2011). Gene Expression Profiling: Changing Face of Breast Cancer Classification and Management. 15, 105-115. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772713/
Yeh, I-T., Mies, C. (2008). Application of Immunohistochemistry to Breast Lesions. Arch Pathol Lab Med 132, 349-358. (Retrieved November 20th 2014): https://www.ncbi.nlm.nih.gov/pubmed/18318578
